Search

Displaying results 681 - 690 of 10000 in total
  1. Drug

    Pamidronic acid

    go.drugbank.com/drugs/DB00282
    ApprovedInvestigational

    [A203111] Pamidronic acid was first described in the literature in 1977. … [A203111] Pamidronic acid was granted FDA approval on 31 October 1991.[L13835]

    Products: PMS-pamidronate
  2. Drug

    Cyanocobalamin

    go.drugbank.com/drugs/DB00115
    ApprovedInvestigationalNutraceutical

    This drug was initially approved by the FDA in 1942 [FDA label]. … The _cyano_ form, is the most widely used form in supplements and prescription drugs [A175255], [FDA label].

    Mixtures: Children's Chew Multi & Min Tab, Childrens Chew Multi Vitamin TabProducts: CIANOCOBALAMINA EG, VITAMIN B12 RATIOPHARM N
  3. Drug

    Mycophenolate mofetil

    go.drugbank.com/drugs/DB00688
    ApprovedInvestigational

    [L7363] It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995. … [A180799,A180805] Previously, mycophenolic acid (MPA) was administered to individuals with autoimmune diseases beginning in the 1970s, but was discontinued due to gastrointestinal effects and concerns

    Synonyms: 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoateProducts: Mycophenolatmofetil Accord 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
  4. Drug

    Albumin human

    go.drugbank.com/drugs/DB00062
    ApprovedInvestigational

    Also known as _Albuminex_ 5% or 25%, one brand of human serum albumin is prepared from the pooled plasma of US donors in FDA-licensed facilities in the US [F229]. … This is a biosimilar drug to existing human serum albumin and was approved for a biological license at both 5% and 25% concentrations by the FDA on June 21, 2018 [L3101].

    Products: Pulmocis 2 mg Kit für ein radioaktives Arzneimittel, NANOTOP 0,5 mg Kit für ein radioaktives Arzneimittel
  5. Drug

    Olmesartan

    go.drugbank.com/drugs/DB00275
    ApprovedInvestigational

    [A175330] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882] … The angiotensin II receptor blocker (ARB) family of drugs unique in that it blocks all angiotensin II activity, regardless of where or how it was synthesized.

    Mixtures: PMS-olmesartan-hctz, PMS-olmesartan-hctzCategories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    Cyproheptadine

    go.drugbank.com/drugs/DB00434
    ApprovedInvestigational

    [L32474] It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of serotonin syndrome.

    Synonyms: 1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidineProducts: PMS-cyproheptadine HCl Tab 4mg
  7. Drug

    Sunitinib

    go.drugbank.com/drugs/DB01268
    ApprovedInvestigational

    For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. … On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).

    Products: SUNITINIB EG
  8. Target

    Hypoxia-inducible factor 1-alpha

    go.drugbank.com/bio_entities/BE0002374
    TargetHumans

    Functions as a master transcriptional regulator of the adaptive response to hypoxia (PubMed:11292861, PubMed:11566883, PubMed:15465032, PubMed:16973622, PubMed:17610843, PubMed:18658046, PubMed:20624928, PubMed:22009797, PubMed:30125331,...

    Synonyms: Member of PAS protein 1, PAS domain-containing protein 8
  9. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    [L14015] It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER … In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved. In November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339]

  10. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.